Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature

Breast cancer is highly heterogenous with temporal and spatial heterogeneity making it necessary for rebiopsy. DS-8201a, a new potential therapy for human epidermal growth factor receptor 2 (HER2) low expression breast cancer, had been proved that it could overcome heterogenous HER2 expression in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Cheukfai, Ren, Chongyang, Wen, Lingzhu, Chen, Xiaoqing, Chen, Bo, Zhang, Guochun, Wang, Yulei, Li, Kai, Cao, Li, Jia, Minghan, Mok, Hsiaopei, Lai, Jianguo, Xiao, Weikai, Li, Xuerui, Liao, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883389/
https://www.ncbi.nlm.nih.gov/pubmed/35237089
http://dx.doi.org/10.1177/11795549211072880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883389/
https://www.ncbi.nlm.nih.gov/pubmed/35237089
http://dx.doi.org/10.1177/11795549211072880

Ejemplares similares